ASH News Daily 2013 - Day 2 - (Page B-23)
ASH News Daily
Sunday, December 8, 2013
Page B-23
®
FocuS on traineeS
ASH Offers Wealth of Activities and Services to Trainees
T
he ASH annual meeting provides hematology trainees
with a variety of high-quality
educational, career-development,
and networking opportunities. To
help trainees make the most of their
meeting experience, the following
activities and services have been
identified as most relevant to the
unique interests of undergraduates,
medical and graduate students, residents, and fellows (MD and PhD).
These events are open only to
Associate members; Medical Student, Graduate Student, and Resident members; and non-members
in training wearing blue trainee
meeting badges. To receive a blue
badge you must register as an Associate member or a non-member
in training.
Trainee Lounge
Trainees are invited to visit the
Trainee Lounge located in the Great
Hall Foyer of the Ernest N. Morial Convention Center. The lounge
provides a relaxing place for trainees to meet with colleagues, access
the Internet, and recharge with
complimentary refreshments.
Hours:
Sunday, December 8
7:00 a.m. to 5:00 p.m.
ever more complex. The demands
of career and personal life can
seem overwhelming at times. In
this session, Dr. Wun will review
the time management challenges
facing a busy clinician, clinician
scientist, or physician scientist as
well as describe strategies for deal-
Chair: Ted Wun, MD, University of
California - Davis, Sacramento, CA
Time Management and Balance
Speaker: Ted Wun, MD
It seems that lives are becoming
»» TRAINEE EVENTS Page B-27
assessing brentuximab vedotin in
Frontline Peripheral T-cell lymphomas
consider echeloN-2 when making a treatment plan
Patients
CD30-positive mature (peripheral)
T-cell lymphomas, including
systemic ALCL (N = 300)*
Select inclusion criteria:
* Newly diagnosed
* Measurable disease, as
defined by both of the
following:
- FDG-avid disease by PET
- CT tumor burden ≥1.5 cm
* ECOG performance
status 0 to 2
Tuesday, December 10
7:00 a.m. to 12:00 noon
During lunch today and Monday, ASH will offer didactic sessions designed to provide trainees
with an overview of timely and
relevant career-oriented issues.
A boxed lunch will be provided.
Space is available on a first-come,
first-served basis. As seating is
limited, attendees are strongly encouraged to arrive early. No additional participants will be allowed
in the rooms once these sessions
are filled.
Bridging the Translational
Divide: The Role of the PhD
Speaker: Jan A. Nolta, PhD, University of California - Davis,
Sacramento, CA
Translating basic science discoveries to clinical applications is the
major goal of much of biomedical research. One of the barriers
that exists to successful transla-
Phase 3 Trial
Now recruiTiNg
Monday, December 9
7:00 a.m. to 5:00 p.m.
Trainee Simultaneous
Didactic Sessions
Today, 11:15 a.m. - 12:15 p.m.
ing with these challenges and various models for achieving work/
life balance.
Investigational arm
A+CHP regimen† (6-8 cycles)
Brentuximab vedotin
1.8 mg/kg IV on day 1 of each
21-day cycle, plus placebo
replacement for vincristine
Endpoints
Primary endpoint
* Progression-free
survival (PFS)
Secondary endpoints
Standard arm
CHOP regimen† (6-8 cycles)
Vincristine 1.4 mg/m2 IV on
day 1 of each 21-day cycle,
plus placebo replacement for
brentuximab vedotin
* Overall survival
* Overall response rate
* Safety and tolerability
*Eligible subtypes include anaplastic lymphoma kinase (ALK)-positive systemic anaplastic large cell lymphoma (ALCL) with an
International Prognostic Index (IPI) score of ≥2; ALK-negative systemic ALCL; peripheral T-cell lymphoma, not otherwise specified
(PTCL-NOS); angioimmunoblastic T-cell lymphoma (AITL); adult T-cell leukemia/lymphoma (ATLL); enteropathy-associated T-cell
lymphoma (EATL); and hepatosplenic T-cell lymphoma.
Cyclophosphamide 750 mg/m2 and doxorubicin 50 mg/m2 will be administered IV on day 1; 100 mg oral prednisone will be
administered on days 1-5 of each 21-day cycle.
†
To learn more about echeloN-2
* Visit the Seattle Genetics Medical Affairs booth
Eligible patients must
be treatment-naïve
* Contact Seattle Genetics Medical Information
at 866.333.7436 (US only)
STOP
* E-mail clinicaltrials@seagen.com
CHOP
BEFORE
* Visit clinicaltrials.gov (NCT01777152)
seattlegenetics.com
Seattle Genetics and are uS registered trademarks of Seattle Genetics, inc.
Other trademarks are property of their respective owners.
MillenniuM and
are registered trademarks
of Millennium Pharmaceuticals, inc.
Other trademarks are property of their respective owners.
© 2013 Seattle Genetics, inc., Bothell, WA 98021
All rights reserved.
Printed in uSA
Millennium Pharmaceuticals, inc., Cambridge, MA 02139
Copyright © 2013, Millennium Pharmaceuticals, inc. All rights reserved.
17010_sgncln_fa1_echelon.indd 1
uSM/BVM/2013/0025(1)
10/30/13 1:17 PM
Table of Contents for the Digital Edition of ASH News Daily 2013 - Day 2
Table of Contents
ASH News Daily 2013 - Day 2
https://www.nxtbookmedia.com